Publicaciones en las que colabora con María del Val Bermejo Sanz (65)

2024

  1. In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug

    Pharmaceutics, Vol. 16, Núm. 3

  2. Pharmaceutical Compounding in Veterinary Medicine: Suspension of Itraconazole

    Pharmaceutics, Vol. 16, Núm. 5

2022

  1. Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen

    International Journal of Pharmaceutics, Vol. 614

2021

  1. Nuevos hidrogeles para favorecer la cicatrización

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 175-176

2020

  1. Candesartan cilexetil in vitro–in vivo correlation: Predictive dissolution as a development tool

    Pharmaceutics, Vol. 12, Núm. 7, pp. 1-21

  2. New insights of oral colonic drug delivery systems for inflammatory bowel disease therapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 18, pp. 1-30

2018

  1. Closed-Loop Doluisio (Colon, Small Intestine) and Single-Pass Intestinal Perfusion (Colon, Jejunum) in Rat—Biophysical Model and Predictions Based on Caco-2

    Pharmaceutical Research, Vol. 35, Núm. 1

  2. Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter

    European Journal of Pharmaceutical Sciences, Vol. 117, pp. 193-203

  3. Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation

    European Journal of Pharmaceutical Sciences, Vol. 119, pp. 200-207

  4. Ionic Hydrogel Based on Chitosan Cross-Linked with 6-Phosphogluconic Trisodium Salt as a Drug Delivery System

    Biomacromolecules, Vol. 19, Núm. 4, pp. 1294-1304

  5. PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen

    European Journal of Pharmaceutical Sciences, Vol. 115, pp. 119-125

  6. Preclinical models for colonic absorption, application to controlled release formulation development

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 130, pp. 247-259

  7. Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits

    European Journal of Pharmaceutical Sciences, Vol. 120, pp. 123-132

2017

  1. Enhancing Oral Absorption of β-Lapachone: Progress Till Date

    European Journal of Drug Metabolism and Pharmacokinetics, Vol. 42, Núm. 1

  2. Gated Mesoporous Silica Nanocarriers for a "two-Step" Targeted System to Colonic Tissue

    Molecular Pharmaceutics, Vol. 14, Núm. 12, pp. 4442-4453

  3. IVIVC approach based on carbamazepine bioequivalence studies combination

    Pharmazie, Vol. 72, Núm. 8, pp. 449-455

  4. Investigating drug absorption from the colon: Single-pass vs. Doluisio approaches to in-situ rat large-intestinal perfusion

    International Journal of Pharmaceutics, Vol. 527, Núm. 1-2, pp. 135-141

  5. Usefulness of Caco-2/HT29-MTX and Caco-2/HT29-MTX/Raji B coculture models to predict intestinal and colonic permeability compared to Caco-2 monoculture

    Molecular Pharmaceutics, Vol. 14, Núm. 4, pp. 1264-1270

2016

  1. Assessment of the Regulatory Methods for the Comparison of Highly Variable Dissolution Profiles

    AAPS Journal, Vol. 18, Núm. 6, pp. 1550-1561

  2. Development of an ion-pair to improve the colon permeability of a low permeability drug: Atenolol

    European Journal of Pharmaceutical Sciences, Vol. 93, pp. 334-340